Pharming (PHAR) Cash from Financing Activities (2019 - 2025)
Pharming (PHAR) posted Cash from Financing Activities of $1.0 million for Q4 2025, up 103.02% on a QoQ basis from -$34.4 million in Q4 2024, and up 103.02% year-over-year from $511288.8 in Q4 2024.
Pharming (PHAR) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Pharming's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $1.0 million for Q4 2025.
- Quarterly Cash from Financing Activities rose 103.02% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$35.8 million (down 13.28% YoY) and the FY2025 annual result came in at $1.5 million, up 104.34% from the prior year.
- Cash from Financing Activities was $1.0 million for Q4 2025 at Pharming, up from -$34.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $5.2 million in Q3 2023 and bottomed at -$34.4 million in Q4 2024.
- A 5-year average of -$4.6 million and a median of -$2.2 million in 2021 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities tumbled 3858.32% — and 2023, when it soared 372.92%.
- Pharming's Cash from Financing Activities stood at -$2.4 million in 2021, then retreated by 21.39% to -$2.9 million in 2022, then surged by 64.04% to -$1.0 million in 2023, then plunged by 3212.03% to -$34.4 million in 2024, then soared by 103.02% to $1.0 million in 2025.
- Business Quant data shows PHAR's Cash from Financing Activities at $1.0 million in Q4 2025, -$34.4 million in Q4 2024, and -$1.4 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Pharming | 9.02 Bn | 8.96 Bn | 65.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | -34.41 Mn |
| Dec 31, 2024 | -34.41 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |
| Sep 30, 2023 | 5.24 Mn |
| Sep 30, 2023 | 5.24 Mn |
| Jun 30, 2023 | -5.26 Mn |
| Jun 30, 2023 | -5.26 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -1.92 Mn |
| Sep 30, 2022 | -1.92 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -2.84 Mn |
| Sep 30, 2021 | -2.84 Mn |